Press Release

Pilot Programs on Alzheimer's Disease and Type 2 Diabetes

PhRMA February 4, 2014

Washington, D.C. (February 4, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) has joined the National Institutes of Health (NIH),  10 biopharmaceutical companies and several non-profit disease foundations in a partnership to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease.

Announced today, the Accelerating Medicines Partnership (AMP) represents an integrated approach to treatment discovery and seeks to increase the number of new diagnostics and therapies for patients while reducing the time and cost associated with their development.

“PhRMA recognizes the critical importance of collaboration across the scientific community.  As a founding partner of AMP, we believe this exciting public-private partnership holds promise not only for the identification of more validated targets for drug discovery and development in three disease states, but may serve as a model for future progress in this most critical hurdle in finding new medicines for patients,” said Dr. Bill Chin, Executive Vice President of Scientific & Regulatory Affairs.

AMP will begin with three to five-year pilot projects focused on three disease areas: Alzheimer’s, type 2 diabetes and autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus (lupus). 

The initiative seeks to optimize the process for identifying and validating clinically relevant disease targets for drug design.  It also will strive to increase efficiency, improve the clinical trial process and increase the number of and effectiveness of new targeted therapies. Importantly, AMP data and analyses will be publicly accessible to the biomedical community.

More information about AMP can be found at

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit